Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Wave Life Sciences Ltd
WVE | US
7.34
USD-0.24
-3.17%
WVE | US
About Wave Life Sciences Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/04/2026
Close
7.34
Open
7.54
High
7.61
Low
7.29
Wave Life Sciences Ltd. a clinical-stage genetic medicine company designs optimizes and produces novel stereopure oligonucleotides through PRISM a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations modulate protein activity restore the production of functional proteins or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004 a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003 a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531 an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006 the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3 a discovery stage program for the treatment of spinocerebellar ataxia 3 as well as multiple preclinical programs for CNS disorders including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc. Takeda Pharmaceutical Company Limited and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.
View LessWVE | US
Risk
184.4
Sharpe
0.11
Luna's Score
33/100
Recommendation
Sell
Luna says (WVE | US)
What's Working
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
32.1%1 month
184.4%3 months
112.3%6 months
232.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
27.11
Debt to equity
6.57
Debt to assets
0.14
Ent. to EBITDA
-10.12
Ent. to rev.
18.98
PEG
-
Other Fundamentals
EBITDA
-79.37M
MarketCap
1.12B
MarketCap(USD)
1.12B
Div. yield
-
Op. margin
-177.72
Erngs. growth
-
Rev. growth
-10.90
Ret. on equity
-1.92K
Short ratio
2.46
Short perc.
6.34
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.91
Range1M
7.65
Range3M
10.45
Volumes: Market Activity
Rel. volume
0.63
Price X volume
31.22M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -10.12 | - | Cheaper |
| Ent. to Revenue | 18.98 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 27.11 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 112.26 | - | Riskier |
| Debt to Equity | 6.57 | -1.23 | Expensive |
| Debt to Assets | 0.14 | 0.25 | Cheaper |
| Market Cap | 1.12B | - | Emerging |
